AR050261A2 - Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento - Google Patents

Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento

Info

Publication number
AR050261A2
AR050261A2 ARP050102999A ARP050102999A AR050261A2 AR 050261 A2 AR050261 A2 AR 050261A2 AR P050102999 A ARP050102999 A AR P050102999A AR P050102999 A ARP050102999 A AR P050102999A AR 050261 A2 AR050261 A2 AR 050261A2
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
phenyl
pyridyl
fluorine atoms
Prior art date
Application number
ARP050102999A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28675482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR050261(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of AR050261A2 publication Critical patent/AR050261A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)

Abstract

Un compuesto de formula (1), o una sal farmacétuciamente aceptable de dicho compuesto; en la cual R1 es hidrogeno o alquilo (C1-3) opcionalmente sustituído con 1 a 5 átomos de fluor; R2 es hidrogeno o alquilo (C1-3) opcionalmente sustituído con 1 a 5 átomos de fluor; R3 es alquilo (C1-6), cicloalquilo (C3-6), cicloalquil (C3-6)alquilo (C1-3), fenilo, fenilalquilo (C1-3), piridilo, piridilalquilo (C1-3), fenil-N(H)- o piridil-N(H)-, en las que cada uno de los restos alquilo anteriores puede estar opcionalmente sustituído con 1 a 5 átomos de fluor y en las que los citados grupos fenilo y piridilo pueden estar opcionalmente sustituídos con 1 a 3 sustituyentes independientemente seleccionados de cloro, fluor, amino, nitro, ciano, alquil (C1-3)amino, alquilo (C1-3) opcionalmente sustituído con 1 a 3 átomos de fluor y alcoxi (C1-3) opcionalmente sustituído con 1 a 3 átomos de fluor; con la condicion de que cuando R1 sea hidrogeno, R2 no sea hidrogeno, o un compuesto de formula (2), o una sal farmacéuticamente aceptable del mismo; en el cual R3 es alquilo (C1-6), cicloalquilo (C3-6), cicloalquil (C3-6)alquilo (C1-3), fenilo, fenilalquilo (C1-3), piridilo, piridilalquilo (C1-3), fenil-N(H)- o piridil-N(H)-, en las que cada uno de los restos alquilo anteriores puede estar opcionalmente sustituído con 1 a 5 átomos de fluor y en las que los citados restos fenilo y piridilo pueden estar opcionalmente sustituídos con 1 a 3 sustituyentes independientemente seleccionados de cloro, fluor, amino, nitro, ciano, alquil (C1-3)amino, alquilo (C1-3) opcionalmente sustituído con 1 a 3 átomos de fluor, o un compuesto de formula (3) o una sal farmacéuticamente aceptable del mismo, en el cual R1 es hidrogeno o alquilo (C1-6) opcionalmente sustituído con 1 a 5 átomos de fluor; y R3 es alquilo (C1-6), cicloalquilo (C3-6), cicloalquil (C3-6)alquilo (C1-3), fenilo, fenilalquilo (C1-3), piridilo, piridilalquilo (C1-3), fenil-N(H)- o piridil-N(H)-, en las que cada uno de los restos alquilo anteriores puede estar opcionalmente sustituído con 1 a 5 átomos de fluor y en las que los citados restos fenilo y piridilo pueden estar opcionalmente sustituídos con 1 a 3 sustituyentes independientemente seleccionados de cloro, fluor, amino, nitro, ciano, alquil (C1-3)amino, alquilo (C1-3) opcionalmente sustituído con 1 a 3 átomos de fluor y alcoxi (C1-3) opcionalmente sustituído con 1 a 3 átomos de fluor. También se dan a conocer composiciones farmacéuticas que los contienen y su uso para preparar un medicamento. Estos compuestos y sus sales farmacéuticamente aceptables se unen a la subunidad alfa-2-delta (alfa2delta) de un canal de calcio y son utiles en el tratamiento de una variedad de trastornos psiquiátricos del dolor y otros.
ARP050102999A 2002-03-28 2005-07-20 Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento AR050261A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36841302P 2002-03-28 2002-03-28

Publications (1)

Publication Number Publication Date
AR050261A2 true AR050261A2 (es) 2006-10-11

Family

ID=28675482

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030101060A AR039154A1 (es) 2002-03-28 2003-03-26 Aminoacidos con afinidad por la proteina alfa-2-delta
ARP050102999A AR050261A2 (es) 2002-03-28 2005-07-20 Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030101060A AR039154A1 (es) 2002-03-28 2003-03-26 Aminoacidos con afinidad por la proteina alfa-2-delta

Country Status (43)

Country Link
US (3) US7064147B2 (es)
EP (2) EP1492761B1 (es)
JP (2) JP3831379B2 (es)
KR (2) KR100694719B1 (es)
CN (2) CN100462351C (es)
AP (1) AP1791A (es)
AR (2) AR039154A1 (es)
AU (1) AU2003208538B2 (es)
BR (1) BR0308814A (es)
CA (1) CA2480872C (es)
CR (1) CR7501A (es)
CU (1) CU23331B7 (es)
CY (1) CY1109304T1 (es)
DE (1) DE60328469D1 (es)
DK (1) DK1492761T3 (es)
EA (2) EA008709B1 (es)
EC (1) ECSP045319A (es)
ES (1) ES2327910T3 (es)
GE (2) GEP20084298B (es)
GT (2) GT200300072AA (es)
HK (1) HK1076627A1 (es)
HR (2) HRP20040891A2 (es)
IL (2) IL164110A0 (es)
IS (2) IS7451A (es)
MA (1) MA27188A1 (es)
MX (1) MXPA04009373A (es)
MY (1) MY131424A (es)
NI (1) NI200300043A (es)
NO (2) NO20044614L (es)
NZ (2) NZ541320A (es)
OA (1) OA12795A (es)
PA (1) PA8570001A1 (es)
PE (1) PE20040349A1 (es)
PL (1) PL209750B1 (es)
PT (1) PT1492761E (es)
RS (2) RS83604A (es)
SI (1) SI1492761T1 (es)
TN (1) TNSN04186A1 (es)
TW (1) TWI225864B (es)
UA (2) UA80018C2 (es)
UY (1) UY27738A1 (es)
WO (1) WO2003082807A2 (es)
ZA (1) ZA200407536B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129693A1 (de) * 2001-06-22 2003-01-02 Jan Loock Verfahren zur extrakorporalen qualitativen und/oder quantitativen Erfassung neurotoxischer Substanzen im Blutplasma eines Individuums
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
WO2005002585A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005030184A2 (en) * 2003-09-25 2005-04-07 Warner-Lambert Company Llc Therapeutic beta aminoacids
MXPA06003395A (es) * 2003-09-25 2006-06-08 Warner Lambert Co Aminoacidos con afinidad por la proteina a2d.
PT1727620E (pt) * 2004-03-12 2007-11-05 Warner Lambert Co Ligandos de biofosfina c1-simétricos e a sua utilização na síntese assimétrica da pregabalina
BRPI0513028A (pt) * 2004-07-09 2008-04-22 Warner Lambert Co preparação de beta-aminoácidos tendo afinidade para a proteìna alfa-2-delta
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
US20080194841A1 (en) * 2005-03-24 2008-08-14 Pfizer Inc. Preparation of Optically Pure Beta-Amino Acids Having Affinity for the Alpha-Delta Protein
WO2007052134A1 (en) * 2005-11-04 2007-05-10 Pfizer Limited (2s)-2-aminomethyl-5-ethyl heptanoic acid its pharmaceutical use
EP1954260A2 (en) * 2005-11-17 2008-08-13 Pfizer Limited Isocystene derivatives for the treatment of pain
MX2008011396A (es) * 2006-03-06 2008-09-18 Pfizer Prod Inc Ligandos alfa-2-delta para sueño no reconstituyente.
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
US20110124705A1 (en) * 2009-11-24 2011-05-26 Xenoport, Inc. Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
CN103717602B (zh) 2011-05-17 2016-11-09 加利福尼亚大学董事会 激酶抑制剂
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CN103164756A (zh) * 2011-12-12 2013-06-19 苏州艾隆科技有限公司 贵重药品的管理方法及其系统
RS58956B1 (sr) 2012-09-10 2019-08-30 Principia Biopharma Inc Jedinjenja pirazolopirimidina kao inhibitori kinaze
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
ES2841248T3 (es) 2014-02-21 2021-07-07 Principia Biopharma Inc Sales y forma sólida de un inhibidor de BTK
PT3233103T (pt) 2014-12-18 2021-01-18 Principia Biopharma Inc Tratamento de pênfigo
MA42242A (fr) 2015-06-24 2018-05-02 Principia Biopharma Inc Inhibiteurs de la tyrosine kinase
KR102515813B1 (ko) 2016-06-29 2023-03-30 프린시피아 바이오파마, 인코퍼레이티드 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1377736A (fr) * 1962-12-21 1964-11-06 Hoffmann La Roche Procédé pour la préparation d'acides amino-carboxyliques
FR1377366A (fr) 1963-08-19 1964-11-06 Dispositif de protection de sécurité pour appareils électriques
KR880007441A (ko) * 1986-12-11 1988-08-27 알렌 제이.스피겔 스피로-치환된 글루타르아미드 이뇨제
AU7168091A (en) 1989-12-22 1991-07-24 Schering Corporation Mercaptocycloacyl aminoacid endopeptidase inhibitors
US5614498A (en) 1990-06-07 1997-03-25 Banyu Pharmaceutical Co., Ltd. Endothelin antagonistic substance
US5011066A (en) * 1990-07-27 1991-04-30 Motorola, Inc. Enhanced collapse solder interconnection
US5239113A (en) 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof
EP0561758A3 (en) 1992-03-18 1995-04-05 Monsanto Co Method of preparing optically active homo-beta-amino acids
US5578606A (en) * 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
AU684878B2 (en) 1993-11-24 1998-01-08 Merck & Co., Inc. Compounds and the use thereof to promote the release of growth hormone(s)
CA2178829A1 (en) 1993-12-12 1995-06-15 Yigal Cohen A novel method to protect plants from fungal infection
US5472830A (en) 1994-04-18 1995-12-05 Ocg Microelectronic Materials, Inc. Non-corrosion photoresist stripping composition
DE69709742T2 (de) 1996-07-12 2002-08-08 Searle & Co Asymmetrische synthese von chiralen beta-aminosäuren
DE69737719D1 (de) * 1996-10-23 2007-06-21 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
GB2323594A (en) 1997-03-25 1998-09-30 Victor Martin 2-amino-alkanoic acid derivatives, 2-amino alcohols and diamines
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
US6011066A (en) 1998-02-02 2000-01-04 Veterans General Hospital-Taipei Method for treating septic shock
AU755273B2 (en) 1998-03-16 2002-12-05 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
EP1013769A1 (en) 1998-12-22 2000-06-28 Dsm N.V. Process for the enzymatic preparation of amino acid derivatives with enhanced optical purity
FR2791982B1 (fr) 1999-04-06 2002-12-27 Inst Nat Sante Rech Med Inhibiteurs de lta4 hydrolase et leurs applications therapeutiques.
OA11962A (en) * 1999-06-10 2006-04-17 Warner Lambert Co Mono-and disubstituted 3-propyl gamma-aminobutyricacids.
EP1294854A2 (en) * 2000-05-16 2003-03-26 Warner-Lambert Company Cell line for the expression of an alpha2-delta2 calcium channel subunit
AU2001258543A1 (en) 2000-05-17 2001-11-26 Medivir Uk Limited Branched amino acids
NZ525143A (en) 2000-09-14 2005-12-23 Gruenenthal Chemie Beta-thio-amino acids
DE10048715A1 (de) 2000-09-30 2004-05-19 Grünenthal GmbH Verwendung von Aminosäure zur Behandlung von Schmerz
IL157845A0 (en) * 2001-03-13 2004-03-28 Univ Kingston Anti-epileptogenic agents
NI200300043A (es) * 2002-03-28 2003-11-05 Warner Lambert Co AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA.
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
CN1228312C (zh) * 2002-12-27 2005-11-23 中国科学院化学研究所 以酮为原料合成β—氨基酸的方法

Also Published As

Publication number Publication date
GEP20074123B (en) 2007-06-11
AP1791A (en) 2007-10-15
WO2003082807A2 (en) 2003-10-09
HRP20050764A2 (en) 2006-02-28
CR7501A (es) 2005-01-24
MXPA04009373A (es) 2005-01-25
CN100462351C (zh) 2009-02-18
US20060154972A1 (en) 2006-07-13
KR20040094882A (ko) 2004-11-10
SI1492761T1 (sl) 2009-12-31
US7517909B2 (en) 2009-04-14
KR100694719B1 (ko) 2007-03-16
CN1653036A (zh) 2005-08-10
PL209750B1 (pl) 2011-10-31
NZ541320A (en) 2007-01-26
CA2480872C (en) 2011-02-15
TW200305576A (en) 2003-11-01
JP2005521723A (ja) 2005-07-21
DK1492761T3 (da) 2009-09-28
UA80116C2 (en) 2007-08-27
EA200401127A1 (ru) 2005-06-30
HRP20040891A2 (en) 2004-12-31
CU23331B7 (es) 2008-12-24
CN1817854A (zh) 2006-08-16
JP2006028189A (ja) 2006-02-02
KR100630981B1 (ko) 2006-10-04
WO2003082807A3 (en) 2003-12-24
UA80018C2 (en) 2007-08-10
EP1492761B1 (en) 2009-07-22
KR20060007446A (ko) 2006-01-24
ZA200407536B (en) 2006-01-25
GT200300072AA (es) 2006-08-23
ES2327910T3 (es) 2009-11-05
EP1614675A2 (en) 2006-01-11
MA27188A1 (fr) 2005-01-03
PL373363A1 (en) 2005-08-22
HK1076627A1 (en) 2006-01-20
JP3831379B2 (ja) 2006-10-11
AP2004003144A0 (en) 2004-09-30
CY1109304T1 (el) 2014-07-02
EP1614675A3 (en) 2006-03-29
NI200300043A (es) 2003-11-05
PE20040349A1 (es) 2004-06-19
UY27738A1 (es) 2003-10-31
AU2003208538A1 (en) 2003-10-13
US20030195251A1 (en) 2003-10-16
PA8570001A1 (es) 2003-12-10
EA200501497A1 (ru) 2006-06-30
RS83604A (en) 2007-02-05
AU2003208538B2 (en) 2009-07-16
NZ535364A (en) 2007-05-31
NO20044614L (no) 2004-12-01
DE60328469D1 (de) 2009-09-03
TNSN04186A1 (fr) 2007-03-12
OA12795A (en) 2006-07-18
GT200300072A (es) 2004-01-21
ECSP045319A (es) 2004-11-26
EP1492761A2 (en) 2005-01-05
IS7451A (is) 2004-09-16
TWI225864B (en) 2005-01-01
US7064147B2 (en) 2006-06-20
IL169820A0 (en) 2007-07-04
IS7951A (is) 2005-07-21
PT1492761E (pt) 2009-09-03
GEP20084298B (en) 2008-01-25
IL164110A0 (en) 2005-12-18
JP3857714B2 (ja) 2006-12-13
US20050272783A1 (en) 2005-12-08
RS20050667A (en) 2007-02-05
BR0308814A (pt) 2005-01-04
EA008709B1 (ru) 2007-06-29
CA2480872A1 (en) 2003-10-09
MY131424A (en) 2007-08-30
AR039154A1 (es) 2005-02-09
NO20053918L (no) 2004-12-01

Similar Documents

Publication Publication Date Title
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
AR033306A1 (es) Compuestos
AR024060A1 (es) Nuevos compuestos farmaceuticamente activos
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
AR030959A1 (es) Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen
PA8620301A1 (es) Inhibidores heterociclil amino de 11-beta-hidrosiesteroide deshidrogenasa tipo 1
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
PA8609201A1 (es) Piridinonas sustituidas
SE0202463D0 (sv) Novel compounds
UY27740A1 (es) Nuevos compuestos
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR044829A1 (es) Derivados de bis-4-cloro fenil pirazinas
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
SV2004001555A (es) Difenilazetidinonas cationicamente sustituidas, procesos para su preparacion, medicamentos que contienen estos compuestos y sus usos
PE20050012A1 (es) Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2
PE20040907A1 (es) Derivados de anilinopirazol
SE0302546D0 (sv) New compounds
AR012723A1 (es) Derivados triptolidos utiles en el tratamiento de enfermedades autoinmunes y usos en la fabricacion de medicamentos
AR043253A1 (es) 4-[(2,4-dicloro-5-metoxifenil)amino] -6- alcoxi-3-quinolina carbonitrilos para el tratamiento de lesiones isquemicas
AR041898A1 (es) Derivados de 4(fenil-piperazinil-metil) benzamida y sus usos para el tratamiento del dolor y desordenes gastrointestinales
AR046022A1 (es) Aminoacidos con afinidad por la proteina alfa 2 gamma. composiciones farmaceuticas.
AR041678A1 (es) Formas cristalinas de clorhidrato de donepezil
PE20040669A1 (es) Derivados de fenilalanina enamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure